Newsflash:
- Many Drug Labels Missing Dose, Safety Info for Kids
- Lilly Oncology to Highlight Final Results for Phase III Study in Most Common Form of Lung Cancer
- J&J Opens Doxil Rationing Program to New Patients
- FDA Issues Safety Label Changes for Fingolimod
- FDA Backs Pill to Block HIV Infection
- FDA Advisers Recommend Approving Arena Weight-Loss Drug
For Lilly, Rocky Year Ahead
Wall Street Journal (01/06/12) Loftus, Peter
Eli Lilly said that it expects profit to decline as much as 20 percent for 2012 and signaled a steeper sales decline for its big-selling antipsychotic Zyprexa, which recently lost patent protection. The drug maker's 2012 outlook contemplates a bigger drop in earnings than Wall Street was bracing for.
Abstract News © Copyright 2011
INFORMATION, INC.
Sponsor Highlights
Our Sponsors:
Sitemap
© Pharmacist e-Link
